Martens et al, Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice, JACC: Basic to Translational Science (2024). DOI: 10.1016/j.jacbts.2024.07.006 ...

Just as semaglutide products like Ozempic revolutionize the world ... have discovered that weekly inoculations of the bacteria Mycobacterium vaccae prevent mice from gaining any weight when on a ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

It’s been a year of buzzworthy health trends, and few have dominated the conversation quite like semaglutide, the active ingredient in the weight loss drugs Ozempic and Wegovy. From Hollywood A ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

The research, published in JACC: Basic to Translational Science, found that the popular drug decreased heart muscle mass in lean and obese mice as well as in lab-grown human heart cells. However, ...